<DOC>
	<DOCNO>NCT00489151</DOCNO>
	<brief_summary>Liver disease due hepatitis B reactivation serious cause morbidity mortality hepatitis B infect patient treated chemotherapy . We previously show pre-emptive use lamivudine , one drastically reduce liver-related morbidity mortality patient . However , due development hepatitis B virus resistance lamivudine , hepatitis B infect patient still develop hepatitis . This research study aim compare use adefovir dipivoxil lamivudine hepatitis B infect patient treated chemotherapy . Both drug approve treatment hepatitis B infection United States , European Union Hong Kong . All patient recruit study receive study medication , either lamivudine 100 mg daily adefovir dipivoxil 10 mg daily cover entire period chemotherapy 72 week . All patient follow-up additional 24 week thereafter . Altogether , 70 subject recruit Queen Mary Hospital , Hong Kong SAR . This open-label study , mean patient study doctor know treatment subject assign . If subject decides take part study find eligible , he/she randomly ( like flip coin ) assign one follow dose group : Lamivudine ( 100 mg ) tablet Adefovir dipivoxil ( 10 mg ) tablet</brief_summary>
	<brief_title>A Randomized Study Comparing Lamivudine Versus Adefovir Dipivoxil Prevention zHBV Reactivation HBsAg Seropositive Patients Undergoing Cytotoxic Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>HBsAg+ , nucleoside/nucleotide analogue na√Øve , malignant disease iv chemotherapy HCV+ HDV+</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>HBV</keyword>
</DOC>